Pharmaceutical Technology1h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...
Pharmaceutical Technology1h
Sonnet BioTherapeutics secures EU patent for FHAB technology
Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) ...
Pharmaceutical Technology2h
Will European PFAS ban disrupt pharma supply chains?
A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the ...
Pharmaceutical Technology4h
FDA RMAT designation for Beacon’s retinitis pigmentosa treatment
The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...
Pharmaceutical Technology18h
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...
Pharmaceutical Technology19h
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Pharmaceutical Technology19h
Allakos cuts 75% of workforce after chronic hives trial failure
A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.
Pharmaceutical Technology22h
Can-Fite BioPharma secures US patent for Namodenoson
Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.